Equitable access to high-cost pharmaceuticals
Equitable Access to High-Cost Pharmaceuticals seeks to aid the development and implementation of equitable public health policies by pharmaco-economics professionals, health economists, and policymakers.
Uloženo v:
| Hlavní autor: | |
|---|---|
| Médium: | E-kniha Kniha |
| Jazyk: | angličtina |
| Vydáno: |
London
Academic Press
2018
Elsevier Science & Technology Academic Press, an imprint of Elsevier |
| Vydání: | 1 |
| Témata: | |
| ISBN: | 9780128119457, 0128119454 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
Obsah:
- 10.4.5 - Biosimilar Medicines -- 10.5 - Strategies at european level -- 10.6 - Outlook -- Abbreviations -- References -- Chapter 11 - Access to High-Cost Medicines in Australia -- 11.1 - Introduction -- 11.2 - Value-based funding -- 11.3 - Pricing policies -- 11.4 - Coverage with evidence development -- 11.5 - Access to non-pbs funded high-cost medicines -- 11.6 - Challenges for the future -- 11.7 - Better information for the public and engagement in decision-making -- 11.8 - Conclusion -- References -- Further readings -- Chapter 12 - Access to High-Cost Medicines in New Zealand -- 12.1 - Introduction -- 12.2 - Approval of medicines in new zealand -- 12.3 - Pharmac -- 12.4 - Subsidised and partly subsidised medications -- 12.5 - Special authority pharmaceuticals -- 12.6 - Exceptions -- 12.7 - Unapproved medicines -- 12.8 - Early access programmes -- 12.9 - Clinical trials -- 12.10 - Rare condition pilot -- 12.11 - Crowdfunding -- 12.12 - Future of access to high-cost medicines in new zealand -- 12.13 - Conclusion -- References -- Chapter 13 - Access to High-Cost Medicines in Wales -- 13.1 - Introduction -- 13.1.1 - Developments in Wales -- 13.1.2 - Recommendations Made By AWMSG -- 13.2 - The appraisal process -- 13.2.1 - Special Status Considerations -- 13.2.2 - Other Routes to Accessing Medicines -- 13.3 - The appraisal criteria -- 13.3.1 - Clinical Effectiveness -- 13.3.2 - Comparative Safety -- 13.3.3 - Cost-Effectiveness -- 13.3.4 - Deviation from the Cost-Effectiveness Threshold Range -- 13.3.5 - Budget Impact -- 13.4 - Consideration of wider societal issues -- 13.5 - Future challenges -- References -- Index -- Back Cover
- 8.4 - System approach to providing art in uganda -- 8.4.1 - System Strengthening -- 8.5 - Quantification and procurement planning unit -- 8.6 - Streamlining and rationalizing of supply chain -- 8.7 - Ensuring good pharmacy practices at public sector facilities -- 8.8 - Capacity building -- 8.9 - Supervision, performance assessment and recognition strategy -- 8.10 - Pharmaceutical financial management -- 8.11 - Pharmaceutical Management Information -- 8.12 - Web-Based Arv Ordering And Reporting System -- 8.13 - Rxsolution -- 8.14 - Pharmaceutical Information Portal -- 8.15 - Financial and commodity tracking system -- 8.16 - Pharmaceutical Sector Management -- 8.17 - Conclusion -- References -- Chapter 9 - Equitable Access to Biosimilars: An Overview -- 9.1 - Introduction -- 9.2 - Methodology -- 9.3 - Market scope and access of biosimilars -- 9.4 - Price control and patients access -- 9.5 - Barriers towards access to biosimilars -- 9.5.1 - High Expenditure for Development of Biosimilars -- 9.5.2 - Stringent Regulatory Regulations, Legislations and Requirements for Biosimilars -- 9.5.3 - Requirement of Distinguishing Nomenclature for Generic and Originator Brands -- 9.5.4 - Biobetters and Next Generation Biologics -- 9.5.5 - Patients' Concerns -- 9.6 - Knowledge of healthcare professionals about biosimilars -- 9.7 - Conclusion -- References -- Chapter 10 - Access to High-Cost Medicines in Europe -- 10.1 - Introduction -- 10.2 - Definitions -- 10.2.1 - High-Cost Medicines -- 10.2.2 - European Countries -- 10.3 - Challenges of affordable access to high-cost medicines -- 10.3.1 - Limitations in Availability -- 10.3.2 - High Prices and Unsustainable Funding -- 10.4 - Policies of european countries -- 10.4.1 - Managed Entry Agreements -- 10.4.2 - HTA and Pharmacoeconomics -- 10.4.3 - Specific Funding Models -- 10.4.4 - Horizon Scanning
- Cover -- Title Page -- Copyright Page -- Dedication -- Contents -- Contributors -- Foreword -- Chapter 1 - Access to High Cost Medicines: An Overview -- Abbreviations -- 1.1 - Defining HCMs -- 1.2 - Value of HCMs -- 1.3 - Accessibility of HCMs -- 1.4 - Approaches for promoting access to HCMs -- 1.5 - Conclusion -- Note -- References -- Chapter 2 - Health Technology Assessment -- 2.1 - Introduction -- 2.2 - What is health technology assessment (hta)? -- 2.3 - Technologies -- 2.4 - Principles underpinning HTA processes -- 2.5 - Evidence-based decision-making for the subsidy of health technologies -- 2.5.1 - Criteria Used to Inform Subsidy Decisions -- 2.5.2 - Threshold for Value for Money -- 2.5.3 - Considering Multiple Criteria in Decision-making -- 2.6 - Who's involved? Stakeholders at the table -- 2.7 - Future directions in health technology assessment for high cost medicines -- 2.8 - Summary -- References -- Chapter 3 - High-Cost Medicines in England -- 3.1 - Introduction -- 3.2 - Background -- 3.2.1 - Policy in History -- 3.2.2 - National Arrangements -- 3.2.3 - NICE Guidance -- 3.2.4 - The Carter Review -- 3.3 - High-cost drugs -- 3.3.1 - Specialised Services -- 3.3.2 - Cancer Drugs Fund -- 3.3.3 - Hospital Medicines Optimisation -- 3.4 - The way ahead -- 3.5 - Conclusions -- References -- Further Reading -- Chapter 4 - Managed Entry Agreements and High Cost Medicines (European Perspective) -- 4.1 - Rationale for mea -- 4.2 - Definition and taxonomy of mea -- 4.3 - Diffusion of mea in europe -- 4.4 - Impact evaluation and future perspectives -- References -- Chapter 5 - Setting a Public Health Agenda to Support Access to High-Cost Medicines -- 5.1 - Introduction -- 5.2 - The emerging significance of the impact of high-cost medicines -- 5.3 - European cooperation -- 5.4 - G7 and G20 -- 5.5 - The un high-level panel on access to medicines
- 5.6 - Who fair pricing forum -- 5.6.1 - What Is a Fair Price? And How Is Such a Fair Price to Be Achieved? -- 5.6.2 - Towards the Fair Pricing System -- 5.7 - Conclusion -- Acknowledgements -- References -- Chapter 6 - Human Rights and Intellectual Property for Universal Access to New Essential Medicines -- 6.1 - Introduction -- 6.2 - Access to essential medicines in the era of intellectual property and human rights -- 6.2.1 - The WTO TRIPS Agreement-Globalising Intellectual Property Rules -- 6.2.2 - HIV and the Drive for Change in Intellectual Property -- 6.2.3 - The Emergence of Access to Essential Medicines in the Right to Health -- 6.2.4 - Doha Declaration on TRIPS and Public Health -- 6.2.5 - Patents and New Essential Medicines -- 6.3 - Human rights obligations of governments -- 6.3.1 - Maximum Available Resources -- 6.3.2 - Efficient Use of Government Resources -- 6.3.3 - Prioritising Medicines for Reimbursement -- 6.3.4 - Use of Price Control Mechanisms and TRIPs Flexibilities -- 6.4 - Protecting access to medicines in international fora -- 6.4.1 - Human Rights Obligations of the Pharmaceutical Industry -- 6.5 - Conclusion -- References -- Further reading -- Chapter 7 - Access to High Price Medicines in Portugal -- 7.1 - Healthcare in portugal -- 7.2 - Access to medicines in portugal -- 7.3 - Financing of high-cost medicines -- 7.4 - Access to high cost medicines in portugal -- 7.5 - Cancer drugs -- 7.6 - Hepatitis c medicines -- 7.7 - Antiretrovirals -- 7.8 - Immunomodulators -- 7.9 - Orphan drugs -- 7.10 - Access to innovation -- 7.11 - Future challenges -- References -- Further readings -- Chapter 8 - Improving Access to High-Cost Medicines in Low Income Countries in Africa: Creating a Functioning Pharmaceutica... -- 8.1 - Introduction -- 8.2 - High-cost medicines in uganda -- 8.3 - System challenges highlighted by providing art in uganda